Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug;36(8):1523-1526.
doi: 10.1038/s41433-022-01943-5. Epub 2022 Feb 10.

A clinician's guide to network meta-analysis

Mark R Phillips  1 , David H Steel  2   3 , Charles C Wykoff  4   5 , Jason W Busse  1   6   7 , Raveendhara R Bannuru  8 , Lehana Thabane  1   9 , Mohit Bhandari  1   10 , Varun Chaudhary  11   12 ; Retina Evidence Trials InterNational Alliance (R.E.T.I.N.A.) Study Group
Collaborators, Affiliations
Editorial

A clinician's guide to network meta-analysis

Mark R Phillips et al. Eye (Lond). 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

MRP: Nothing to disclose. DHS: Consultant: Gyroscope, Roche, Alcon, BVI; Research Funding for IIS: Alcon, Bayer, DORC, Gyrsocope, Boehringer-Ingelheim – unrelated to this study. CCW: Consultant: Acuela, Adverum Biotechnologies, Inc, Aerpio, Alimera Sciences, Allegro Ophthalmics, LLC, Allergan, Apellis Pharmaceuticals, Bayer AG, Chengdu Kanghong Pharmaceuticals Group Co, Ltd, Clearside Biomedical, DORC (Dutch Ophthalmic Research Center), EyePoint Pharmaceuticals, Gentech/Roche, GyroscopeTx, IVERIC bio, Kodiak Sciences Inc, Novartis AG, ONL Therapeutics, Oxurion NV, PolyPhotonix, Recens Medical, Regeron Pharmaceuticals, Inc, REGENXBIO Inc, Santen Pharmaceutical Co, Ltd, and Takeda Pharmaceutical Company Limited; Research funds: Adverum Biotechnologies, Inc, Aerie Pharmaceuticals, Inc, Aerpio, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Clearside Biomedical, Gemini Therapeutics, Genentech/Roche, Graybug Vision, Inc, GyroscopeTx, Ionis Pharmaceuticals, IVERIC bio, Kodiak Sciences Inc, Neurotech LLC, Novartis AG, Opthea, Outlook Therapeutics, Inc, Recens Medical, Regeneron Pharmaceuticals, Inc, REGENXBIO Inc, Samsung Pharm Co, Ltd, Santen Pharmaceutical Co, Ltd, and Xbrane Biopharma AB – unrelated to this study. JWB: Nothing to disclose. RRB: Research funds: Pfizer – unrelated to this study. LT: Nothing to disclose. MB: Research funds: Pendopharm, Bioventus, Acumed – unrelated to this study. VC: Advisory Board Member: Alcon, Roche, Bayer, Novartis; Grants: Bayer, Novartis – unrelated to this study.

Figures

Fig. 1
Fig. 1. Network diagram from Li et al. (2016) [10] comparing medications for POAG.
Size of nodes represents the number of patients, line thickness represents number of trials.
See this image and copyright information in PMC

References

    1. Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet Lond Engl. 2017;390:415–23. doi: 10.1016/S0140-6736(16)31592-6. - DOI - PubMed
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097. - DOI - PMC - PubMed
    1. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315:1533–7. doi: 10.1136/bmj.315.7121.1533. - DOI - PMC - PubMed
    1. Crowther M, Lim W, Crowther MA. Systematic review and meta-analysis methodology. Blood. 2010;116:3140–6. doi: 10.1182/blood-2010-05-280883. - DOI - PubMed
    1. Leucht S, Kissling W, Davis JM. How to read and understand and use systematic reviews and meta-analyses. Acta Psychiatr Scand. 2009;119:443–50. doi: 10.1111/j.1600-0447.2009.01388.x. - DOI - PubMed

Publication types